Crossfire Oncology

Over Crossfire Oncology

Aberrant functioning of kinases is known to be an important driver in cancer. Targeting hereof has proven to be extremely successful and has already revolutionized the management of numerous types of cancer.

At Crossfire Oncology we approach kinases from three different angles: inhibitors, degraders, and degrader antibody conjugates. This tailored approach allows us to design kinase targeting drugs that aim to maximize the therapeutic benefit for cancer patients.

Adres

• Hoofdkantoor

  Kloosterstraat 95349AB OssNoord-Brabant, Nederland

Team per functiegebied

Gebaseerd op 14 openbare functieprofielen, stand van 3 september 2026.

• Research / R&D12
• Executive / C-Suite2